<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103766</url>
  </required_header>
  <id_info>
    <org_study_id>8736</org_study_id>
    <nct_id>NCT00103766</nct_id>
  </id_info>
  <brief_title>Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion</brief_title>
  <official_title>Randomized Comparison of Two Dose and Frequency Regimens of Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>O'Brien, Jeana D., MD, FACP, FCCP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scott and White Hospital &amp; Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scott, Sherwood and Brindley Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>O'Brien, Jeana D., MD, FACP, FCCP</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the benefit to patients with empyema or complicated
      parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two
      different dose strategies compared with saline placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled pilot study. Patients with empyema and
      complicated parapneumonic effusion who are felt to require fibrinolytic therapy will be
      considered for study enrollment. Enrolled patients will be randomized to one of five
      potential treatment arms (saline placebo, 4 mg once daily, 4 mg twice daily, 10 mg once
      daily, or 10 mg twice daily) in a double-blinded manner.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2004</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for surgical intervention via thoracostomy or open decortication as a result of conservative therapy.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily chest tube drainage</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic improvement</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Empyema</condition>
  <condition>Pleural Effusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Age greater or equal to 18 yrs

          -  Presence of empyema or CPE

        Exclusion Criteria:

          -  Active internal bleeding

          -  Pregnancy

          -  Prior enrollment in this study

          -  Platelet count less than 100,000/mm3

          -  Use of warfarin sodium if INR is greater than 1.7

          -  Use of heparin unless the PTT is less than 1.5 times baseline normal

          -  Known neurological disorders

          -  Current or pre-existing bleeding dyscrasia

          -  Known allergy to Alteplase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeana D O'Brien, MD, FACP, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scott and White Memorial Hospital and Scott, Sherwood and Brindley Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delores Gautier, RN, MSN</last_name>
    <phone>254-724-1769</phone>
    <email>lgautier@swmail.sw.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital &amp; Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delores Gautier, RN, MSN</last_name>
      <phone>254-724-1769</phone>
      <email>lgautier@swmail.sw.org</email>
    </contact>
    <investigator>
      <last_name>Jeana D O'Brien, MD, FACP, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominic R deKeratry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy S Mooring, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2005</study_first_submitted>
  <study_first_submitted_qc>February 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2005</study_first_posted>
  <last_update_submitted>July 31, 2006</last_update_submitted>
  <last_update_submitted_qc>July 31, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2006</last_update_posted>
  <keyword>Alteplase</keyword>
  <keyword>Empyema</keyword>
  <keyword>Complicated Parapneumonic Effusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Empyema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

